By Kate Rawson
A year ago, Pfizer Inc. 's inhaled insulin (Exubera) seemed to be on a fast track to nowhere. Once...
Pfizer's Exubera: Breathing New Life Into Inhaled Insulin
Listen to this article
Dragging a host of safety concerns, Exubera hardly inspired confidence when it went before an FDA advisory committee. But Pfizer proposed an aggressive risk management scheme that won it a dramatic "yes" vote. How one company addressed a drug's safety concerns head-on to win the confidence of FDA's advisors.
Candid conversations with C-suite leaders.
More from Leadership
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.